SA
HCM logo
HUTCHMED (China) Limited(HCM)
Closing price · checked 8:25 PM ETAbout this dataData status
$13.22▼-0.23 (-1.71%)
Extended:$13.22+0.00 (+0.00%)· 8:25 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

HUTCHMED (China) Limited (HCM)

R&D Expenses

$161.54M

TTM · Period ending: · USD

HCM logo

HCM R&D Expenses

Latest reported$161.54M
HCM R&D Expenses ($1.16M → $161.54M)
Powered by
High-resolution chart · PNG

What is r&d expenses?

Research and development spending.

HCM r&d expenses history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

HUTCHMED (China) Limited R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)Change
164,148,985−23.07%
213,365,000−29.60%
303,055,000−21.67%
386,893,000+29.36%
299,086,000+69.27%
176,686,603+92.17%
91,944,000−20.45%
115,583,000+52.53%
75,779,259+13.32%
66,871,000+41.17%
47,368,000+58.35%
29,914,000+567.72%
4,480,024−23.99%
5,894,000−19.15%
7,290,283+13.82%
6,405,278+66.10%
3,856,306−56.22%
8,807,528+56.06%
5,643,644+103.58%
2,772,179+35.42%
2,047,157+76.75%
1,158,191—

Frequently asked questions: HCM r&d expenses

What is HUTCHMED (China) Limited (HCM)'s current r&d expenses?

HUTCHMED (China) Limited (HCM)'s latest reported r&d expenses (TTM) is $161.54M as of Jun 30, 2026. Research and development spending.

How much historical r&d expenses data is available for HCM?

Stock Alarm Pro provides 22 dated annual fiscal periods observations for HUTCHMED (China) Limited (HCM)'s r&d expenses, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare HCM's r&d expenses to peers or set an alert?

You can open HCM's r&d expenses in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on HCM delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.